Transfusion therapy in the intensive care unit

Current Opinion in Anaesthesiology

Volumn 19, Issue 2, 2006, Pages 127-131

  Williams, Adrienne P ^a   Gettinger, Andrew ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Aprotinin (Trasylol); Immunomodulation; Recombinant erythropoietin (rHuEPO, Epogen, Procrit); Recombinant factor VIIa (rFVIIa, NovoSeven); Transfusion related acute lung injury (TRALI)

Indexed keywords

APROTININ; FRESH FROZEN PLASMA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; BLOOD COMPONENT THERAPY; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD STORAGE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COST BENEFIT ANALYSIS; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; ERYTHROCYTE COUNT; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEART INFARCTION; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION RISK; INTENSIVE CARE; INTENSIVE CARE UNIT; LABORATORY DIAGNOSIS; MEDICAL SERVICE; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SEPSIS; STROKE; THROMBOCYTE TRANSFUSION; THROMBOSIS; TRANSFUSION RELATED ACUTE LUNG INJURY; VENOUS THROMBOEMBOLISM;

ANIMALS; APROTININ; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; FACTOR VIIA; HEMOSTATICS; HUMANS; IMMUNOSUPPRESSION; INTENSIVE CARE UNITS; RECOMBINANT PROTEINS;

EID: 33646024355     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000192768.12206.08     Document Type: Review

References (39)

1. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest 2004; 126:249-258. A review article that highlights the diagnosis, pathophysiology, and treatment of TRALI.
2. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33:721-726. A review that covers diagnostic criteria and incidence, as well as a discussion of acute lung injury in relation to TRALI
3. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25:573-577.
4. Kram R, Loer SA. Transfusion-related acute lung injury: lack of recognition because of unawareness of this complication? Eur J Anaesthesiol 2005; 22:369-372.
5. Rajan GR. Severe transfusion-related acute lung injury in the intensive care unit secondary to transfusion of fresh frozen plasma. Anaesth Intensive Care 2005; 33:400-402. A case report that highlights the key steps in diagnosing TRALI.
6. Nakagawa M, Toy P. Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases in one hospital. Transfusion 2004; 44:1689-1694.
7. Nicolle AL, Chapman CE, Carter V, Wallis JP. Transfusion-related acute lung injury caused by two donors with anti-human leucocyte antigen class II antibodies: a look-back investigation. Transfus Med 2004; 64:225-230.
8. Flesch B, Neppert J. Transfusion-related acute lung injury caused by human leucocyte antigen class II antibody. Br J Haematol 2002; 116:673-676.
9. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic events in critically ill patients. Crit Care Med 2005; 33 (3):487-503. Looks at the cost-efficacy of rHuEPO in the critically ill.
10. Gajic O, Moore BS. Transfusion-related acute lung injury. Mayo Clin Proc 2005; 80:766-770. A review of TRALI and its basic pathophysiology.
11. Toy P, Gajic O. Transfusion-related acute lung injury. Anesth Analg 2004; 99:1623-1624. A quick review of TRALI.
12. Wallis JP. Transfusion-related acute lung injury (TRALI) - under-diagnosed and under-reported. Br J Anaesth 2003; 90:573-576.
13. Hill GE, Frawley WH, Griffith KE, et al. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma 2003; 54:908-914.
14. Biedler AE, Schneider SO, Seyfert U, et al. Impact of alloantigens and storage-associated factors on stimulated cytokine response in an in vitro model of blood transfusion. Anesthesiology 2002; 97:1102-1109.
15. Kirkley SA. Proposed mechanisms of transfusion-induced immunomodulation. Clin Diagn Lab Immunol 1999; 6:652-657.
16. Hyllner M, Tylman M, Bengston JP, et al. Complement activation in prestorage leucocyte-filtered plasma. Transfus Med 2004; 14:45-52.
17. Landers DF, Dullye KK. Vascular access and fluid resuscitation in trauma: issues of blood and blood products. Anesth Clin North Am 1999; 17:125-140.
18. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97:1180-1195.
19. Silliman CC, Moore EE, Johnson JL, et al. Transfusion of the injured patient: proceed with caution. Shock 2004; 21:291-299. A review of transfusion risks, as well as leukoreduction and hemoglobin substitutes.
20. Rodriguez RM, Corwin HL, Gettinger A, et al. Nutritional deficiencies and blunted erythropoietin response as a cause of the anemia of critical illness. J Crit Care 2001; 16:36-41.
21. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients. JAMA 2002; 288:2827-2835.
22. Shermock KM, Horn E, Lipsett PA, et al. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005; 33:487-503. Looks at the cost-efficacy of rHuEPO in the critically ill.
23. Rentoul TM, Harrison VL, Shun A. The effect of aprotinin on transfusion requirements in pediatric orthotopic liver transplantation. Pediatr Transplant 2003; 7:142-148.
24. Haas S. Aprotinin - a blood-saving substance. Infus Ther Transfus Med 2002; 29:151-155.
25. Murkin JM, Haig GM, Beer KJ, et al. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg 2000; 82-A:675-684.
26. Janssens M, Joris J, David JL, et al. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology 1994; 80:23-29.
27. Singlbartl G, Kantak S, Munkel H. Transfusion-related cost of adjunct aprotinin application in one-step infected hip revision arthroplasty - cost-minimizing analysis. Infus Ther Transfus Med 2001; 28:74-79.
28. Monroe DM, Hoffman M, Wising H, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:543-547.
29. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7:408-413.
30. Karadimov D, Krassimir B, Nachkov Y, Platikanov V. Use of activated recombinant factor VII (NovoSeven) during neurosurgery. J Neurosurg Anesthesiol 2003; 15:330-332.
31. Slappendel R, Huvers F, Benraad B, et al. Use of recombinant factor VIIa (NovoSeven) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia. Anesthesiology 2002; 96:1525-1527.
32. Brown JB, Emerick KM, Browh DL, et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003; 37:268-272.
33. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology 2004; 100:722-730. A review of hemostasis, including a basic coagulation review, anticoagulants, and rFVIIa uses, both on- and off-label.
34. Gowers CJD, Parr MJA. Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesth Intensive Care 2005; 33:196-200.
35. Levi M, Peteres M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review (review). Crit Care Med 2005; 33:883-890. A review of the current literature surrounding rFVIIa.
36. Poon M-C. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol 2001; 8:312-318.
37. Hind D, Lloyd-Jones M, Makris M, Paisley S. Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia A and inhibitors. Cochrane Database Syst Rev 2005 :3.
38. Corwin HL, Surgenor SD, Gettinger A. Transfusion practice in the critically ill. Crit Care Med 2003; 12 (Suppl.):S668-S671.
39. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med 2004; 32:39-52. A multicenter observational cohort study demonstrating that the number of red blood cell units transfused is an independent predictor of worse clinical outcome.